Business Context and Reporting Period
This Form 8-K filing by Landec Corporation (LNDC) reports significant corporate governance and executive leadership changes effective May 23, 2019. The filing details the immediate resignation of the former CEO and Chairman, the appointment of a new CEO, and the promotion of the Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and executive compensation terms.
Material Changes Versus Prior Period
- CEO Resignation: Molly Hemmeter resigned as President, Chief Executive Officer, and Board member effective immediately.
- CEO Appointment: Albert D. Bolles, Ph.D., a current director, was appointed President and CEO effective immediately.
- Chairman Changes: Steven Goldby retired as Chairman and Board member; Andrew Powell was appointed interim Chairman.
- CFO Promotion: Greg Skinner was promoted to Executive Vice President of Finance and Administration and CFO.
Guidance, Outlook, and Management Commentary
Executive Compensation and Terms:
- Dr. Bolles Salary: Annual base salary of $620,000 plus annual cash incentive awards.
- Equity Grants: Granted an option to purchase 162,000 shares and 55,000 restricted stock units (RSUs). Options vest 1/3 after one year and monthly thereafter; RSUs vest on the third anniversary.
- Severance Provisions:
- Standard Termination: 100% of annual base salary, pro-rated bonus, one-year acceleration of equity vesting, and COBRA health coverage.
- Change of Control: 150% of annual base salary, pro-rated bonus, immediate full vesting of all unvested equity, and COBRA health coverage.
- Non-Solicit: Two-year restriction on soliciting employees, consultants, licensors, or customers.
- Board Nomination: Dr. Bolles has a one-time right to nominate a director to fill a vacancy or for the 2019 annual meeting slate.
CFO Compensation: Greg Skinner's annual base salary increased from $380,000 to $418,000, effective for the 2020 fiscal year.
Management Commentary: The Board highlighted Dr. Bolles' extensive background in food science, including leadership roles at ConAgra Foods and PepsiCo, citing his expertise in product development, innovation, quality, and supply chain management as critical for the Company's packaged consumer food business.
Investor Verification Checklist
- Verify the terms of the Executive Employment Agreement filed as Exhibit 10.1.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the impact of the new CEO's strategic direction on product development and supply chain operations.
- Confirm the vesting schedule and performance metrics for the 162,000 stock options and 55,000 RSUs granted to Dr. Bolles.